Current management of anal canal cancer
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
Squamous cell carcinoma of the anal canal historically has been treated with abdominoperineal resection, resulting in high rates of morbidity and local recurrence. Pioneering work led to the finding that radiation therapy (RT) combined with 5-fluorouracil (5-FU) and mitomycin results in high rates of local control and disease-free and colostomy-free survival without surgery. Prospective randomized trials from Europe and the United States have shown the superiority of RT, 5-FU, and mitomycin over 1) RT alone, 2) RT with 5-FU, and 3) neoadjuvant cisplatin/5-FU with concurrent radiation, cisplatin, and 5-FU. At present, RT with 5-FU and mitomycin is the standard of care for anal cancer patients. Recent advances include the integration of positron emission tomography into staging, radiation treatment planning and monitoring, and the use of intensity modulated RT. European randomized trials are further evaluating the role of cisplatin in the neoadjuvant, concurrent, and adjuvant settings, as well as radiation dose escalation. Other studies are evaluating the use of capecitabine, oxaliplatin, and the anti-epidermal growth factor receptor agent cetuximab with RT in this malignancy.
- Boman BM, Moertel CG, O’Connell MJ, et al.: Carcinoma of the anal canal. A clinical and pathologic study of 188 cases. Cancer 1984, 54:114–125. CrossRef
- Nigro ND, Vaitkevicius VK, Considine B Jr:Combined therapy for cancer of the anal canal: a preliminary report. Dis Colon Rectum 1974, 17:354–356. CrossRef
- Buroker TR, Nigro N, Bradley G, et al.: Combined therapy for cancer of the anal canal: a follow-up report. Dis Colon Rectum 1977, 20:677–678. CrossRef
- Michaelson RA, Magill GB, Quan SH, et al.: Preoperative chemotherapy and radiation therapy in the management of anal epidermoid carcinoma. Cancer 1983, 51:390–395. CrossRef
- Nigro ND, Seydel HG, Considine B, et al.: Combined preoperative radiation and chemotherapy for squamous cell carcinoma of the anal canal. Cancer 1983, 51:1826–1829. CrossRef
- Leichman L, Nigro N, Vaitkevicius VK, et al.: Cancer of the anal canal. Model for preoperative adjuvant combined modality therapy. Am J Med 1985, 78:211–215. CrossRef
- Meeker WR Jr, Sickle-Santanello BJ, Philpott G, et al.: Combined chemotherapy, radiation, and surgery for epithelial cancer of the anal canal. Cancer 1986, 57:525–529. CrossRef
- Epidermoid anal cancer: results from the UKCCCR randomised trial of radiotherapy alone versus radiotherapy, 5-fluorouracil, and mitomycin. UKCCCR Anal Cancer Trial Working Party. UK Co-ordinating Committee on Cancer Research. Lancet 1996, 348:1049–1054.
- Bartelink H, Roelofsen F, Eschwege F, et al.: Concomitant radiotherapy and chemotherapy is superior to radiotherapy alone in the treatment of locally advanced anal cancer: results of a phase III randomized trial of the European Organization for Research and Treatment of Cancer Radiotherapy and Gastrointestinal Cooperative Groups. J Clin Oncol 1997, 15:2040–2049.
- Flam M, John M, Pajak T, et al.: Role of mitomycin in combination with fluorouracil and radiotherapy, and of salvage chemoradiation in the definitive nonsurgical treatment of epidermoid carcinoma of the anal canal: results of a phase III randomized intergroup study. J Clin Oncol 1996, 14:2527–2539.
- Ajani J, Winter K, Gunderson L, et al.: Fluorouracil, mitomycin, and radiotherapy vs fluorouracil, cisplatin, and radiotherapy for carcinoma of the anal canal. A randomized controlled trial. JAMA 2008, 299:1914–1921. CrossRef
- Ajani J, Winter K, Gunderson L, et al.: Intergroup RTOG 98-11: a phase III randomized study of 5-fluoruracil (5-FU), mitomycin, and radiotherapy versus 5-fluorouracil, cisplatin and radiotherapy in carcinoma of the anal canal [abstract]. J Clin Oncol 2006, 24:180s.
- Gunderson LL, Winter K, Ajani J, et al.: Intergroup RTOG 9811 phase III comparison of chemoradiation with 5-FU and mitomycin vs 5-FU and cisplatin for anal canal carcinoma: impact of disease-free, overall and colostomy-free survival [abstract]. Int J Radiat Oncol Biol Phys 2006, 66:S24.
- Trautmann TG, Zuger JH: Positron emission tomography for pretreatment staging and posttreatment evaluation in cancer of the anal canal. Mol Imaging Biol 2005, 7:309–313. CrossRef
- Cotter SE, Grigsby PW, Siegel BA, et al.: FDG-PET/CT in the evaluation of anal carcinoma. Int J Radiat Oncol Biol Phys 2006, 65:720–725.
- Anderson C, Koshy M, Staley C, et al.: PET-CT fusion in radiation management of patients with anorectal tumors. Int J Radiat Oncol Biol Phys 2007, 69:155–162.
- Schwarz J, Siegel BA, Dehdashti F, et al.: Tumor response and survival predicted by post-therapy FDG-PET/CT in anal cancer. Int J Radiat Oncol Biol Phys 2007, 71:180–186.
- John M, Pajak T, Flam M, et al.: Dose escalation in chemoradiation for anal cancer: preliminary results of RTOG 92-08. Cancer J Sci Am 1996, 2:205–211.
- Roohipour R, Patil S, Goodman K: Squamous-cell carcinoma of the anal canal: predictors of treatment outcome. Dis Colon Rectum 2008, 51:147–153. CrossRef
- Glynne-Jones R, Hoskin P: Neoadjuvant cisplatin chemotherapy before chemoradiation: a flawed paradigm. J Clin Oncol 2007, 25:5281–5286. CrossRef
- De Ruysscher D, Pijls-Johannesma M, Bentzen SM, et al.: Time between the first day of chemotherapy and the last day of chest radiation is the most important predictor of survival in limited-disease small-cell lung cancer. J Clin Oncol 2006, 24:1057–1063. CrossRef
- Brade AM, Tannock IF: Scheduling of radiation and chemotherapy for limited-stage small-cell lung cancer: repopulation as a cause of treatment failure? J Clin Oncol 2006, 24:1020–1022. CrossRef
- James R, Meadows H: The second UK phase III anal cancer trial of chemoradiation and maintenance therapy (ACTII): preliminary results on toxicity and outcome. Proc Am Soc Clin Oncol 2003, 22:1151.
- Salama JK, Mell LK, Schomas DA, et al.: Concurrent chemotherapy and intensity-modulated radiation therapy for anal canal cancer patients: a multicenter experience. J Clin Oncol 2007, 25:4581–4586. CrossRef
- Current management of anal canal cancer
Current Oncology Reports
Volume 11, Issue 3 , pp 186-192
- Cover Date
- Print ISSN
- Online ISSN
- Current Science Inc.
- Additional Links